Issues and perspectives on the biocompatibility and immunotoxicity evaluation of implanted controlled release systems.
暂无分享,去创建一个
[1] James M. Anderson,et al. In vivo biocompatibility studies of medisorb® 65/35 D,L-lactide/glycolide copolymer microspheres , 1993 .
[2] James M. Anderson,et al. In vivo biocompatibility of implantable delivery systems and biomaterials , 1994 .
[3] L. Martin,et al. Transgenic mice as a model to test the immunogenicity of proteins altered by site-specific mutagenesis. , 1989, Molecular biology & medicine.
[4] James M. Anderson,et al. Biocompatibility studies of naltrexone sustained release formulations , 1992 .
[5] T. Stewart. Models of human endocrine disorders in transgenic rodents , 1993, Trends in Endocrinology & Metabolism.
[6] I. Cohen,et al. Autoimmune disease models : a guidebook , 1994 .
[7] M. Chapekar. Regulatory concerns in the development of biologic-biomaterial combinations. United States Food and Drug Administration. , 1996, Journal of biomedical materials research.
[8] R. Greenwald,et al. CRC handbook of animal models for the rheumatic diseases , 1988 .
[9] M. Shive,et al. Biodegradation and biocompatibility of PLA and PLGA microspheres , 1997 .
[10] Brooks M. Boyd,et al. Recombinant human growth hormone poly(lactic-co-glycolic acid) (PLGA) microspheres provide a long lasting effect , 1997 .